TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06531499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA617
Description: \[177Lu\]Lu-PSMA-617 will be administered as an intravenous infusion at a dose of 7.4 GBq (200mCi) (+/- 10%), every 6 weeks for up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) analogues
Description: Anatomical Therapeutic Chemical \[ATC\] code L02AE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH) antagonists
Description: Degarelix, Relugolix
Study: NCT06487650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep intervention
Description: At the beginning of the intervention, participants will have an orientation and overview of the program. Then, participants will follow the curriculum of modules, and professional feedback to complete the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants in control group will follow standardized usual care and a perinatal health booklet
Study: NCT05313334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GAMBIT Task
Description: The GAMBIT task is a novel inhibitory control task. Participants in the Healthy Control group will receive the GAMBIT intervention repeatedly over the study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GAMBIT Task
Description: The GAMBIT task is a novel inhibitory control task. Participants in the Healthy Control group will receive the GAMBIT intervention repeatedly over the study period.
Study: NCT06771934

Intervention type: BIOLOGICAL
Intervention: Allergen-specific immunotherapy(AIT)
Description: Allergen-Specific Immunotherapy(AIT) Protocol: using the house dust mite allergen preparation (Alutard, ALK Company, Denmark). The treatment course was divided into the initial treatment stage and the maintenance treatment stage. The initial treatment stage, also known as the dose accumulation stage, involved injecting the vaccine once a week and usually lasted for 15 weeks. For highly sensitive patients, treatment was carried out according to the dose guidelines for high sensitivity. The maximum dose in the initial treatment stage was the maintenance dose. After reaching the maintenance dose, the first maintenance injection was given 2 weeks later, the second maintenance injection was given 4 weeks later, and thereafter, a vaccine injection was carried out every 4 - 8 weeks.

Intervention type: BIOLOGICAL
Intervention: Allergen-specific immunotherapy(AIT)
Description: Allergen-Specific Immunotherapy(AIT) Protocol: using the house dust mite allergen preparation (Alutard, ALK Company, Denmark). The treatment course was divided into the initial treatment stage and the maintenance treatment stage. The initial treatment stage, also known as the dose accumulation stage, involved injecting the vaccine once a week and usually lasted for 15 weeks. For highly sensitive patients, treatment was carried out according to the dose guidelines for high sensitivity. The maximum dose in the initial treatment stage was the maintenance dose. After reaching the maintenance dose, the first maintenance injection was given 2 weeks later, the second maintenance injection was given 4 weeks later, and thereafter, a vaccine injection was carried out every 4 - 8 weeks.

Intervention type: BIOLOGICAL
Intervention: omalizumab
Description: Omalizumab Treatment Protocol: The dosage and administration frequency (once every 2 weeks or once every 4 weeks) of omalizumab were determined based on the patients' pretreatment serum total IgE (kU/L), age, and body weight (kg). Each dosage ranged from 15 to 600 mg and was administered subcutaneously. If the dosage was ≤ 150 mg, it was injected subcutaneously at 1 site; otherwise, it was injected subcutaneously at 1 to 4 sites respectively. After the first 3 injections, patients were observed in the hospital for at least 2 hours, and after the 4th and subsequent injections, they were observed for at least 30 minutes. During the treatment period, the background medications for asthma control were adjusted according to the patient's condition.
Study: NCT06771765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chia Seeds
Description: Chia seeds will be added to soup, bread, and a cookie, and these food items will be served as a lunch meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hemp Seeds
Description: Hemp seeds will be added to soup, bread, and a cookie, and these food items will be served as a lunch meal.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo) group
Description: This intervention is a lunch meal made from standard recipes. This intervention is the placebo control intervention.
Study: NCT06770218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic girdle stability training and therapeutic tapping
Description: pelvic girdle stability training performed along with therapeutic taping in experimental group tapping involves applying strips one and two over the paraspinal region from l4 to t1 in a caudo cephalic directions. strips 3 and 4 along the lower portion of trapezius with a medially directed force from the acromion process to T12 obliquely. total session time 45 minutes to 60 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: pelvic girdle stability training only
Description: participates engaged in pelvic girdle stability training focusing on exercises therapeutics taping was not be administrated during these stability exercises. excercise include pelvic brigde, one leg bridge, calm exercise for gluteus medius, leg lift 4 point kneelig arm lift
Study: NCT06772870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-216P2
Description: DT-216P2 will be administered as subcutaneous injection, subcutaneous infusion and intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline solution will be used as placebo control.
Study: NCT06021704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced home health aide training in dementia and dementia-related behaviors
Description: 8 hours (2 instructional days) of enhanced curriculum dementia-specific instruction for home health aides
Study: NCT06023394

Intervention type: DEVICE
Group type: OTHER
Intervention: Laryngeal Mask Airway
Description: Laryngeal mask airway will be used as an airway device for Cohort A in the standard fashion.

Intervention type: DEVICE
Group type: OTHER
Intervention: Endotracheal Tube Device
Description: Endotracheal tube airway will be used as an airway device for Cohort B in the standard fashion.
Study: NCT06465381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention
Description: All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Usual Care
Description: All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Cognitive Behavioral Therapy for Suicide Prevention
Description: All behavioral interventions will be provided by a trained nonspecialist healthcare worker, descriptions of each intervention can be found under treatment arm/group descriptions.
Study: NCT06770712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The patients were asked to sit in front of a table at an appropriate height and rest their arms on the table. A mirror was placed between both arms. The mirror was positioned so that the reflection of the healthy extremity overlapped with the paralytic extremity. In this way, the movements of the healthy upper extremity were viewed through the mirror, creating a visual movement illusion for the hemiplegic upper extremity. During the mirror therapy, exercises including forearm supination-pronation, wrist flexion-extension, finger flexion-extension, finger counting, grasping and releasing a cup, grasping and releasing a ball, and writing with a pen were performed. First, 30 minutes of bilateral TENS therapy were applied, followed by 30 minutes of mirror therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Received stimulation on the extensor muscles of the hand fingers of both the intact and paretic sides, with a frequency of 100 Hz, pulse width of 200 microseconds, and a biphasic symmetric pulse for 30 minutes. The current intensity was adjusted to a level that induced visible muscle contractions and was set to twice the sensory threshold. Self-adhesive electrodes, measuring 5x5 cm, were placed on the extensor surface of the forearm, 5 cm distal to the olecranon, parallel to the long axis of the muscle. Electrical stimulation was applied using the Cefar Rehab X2 device (DJO France SAS).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Received stimulation on the extensor muscles of the hand fingers of both the intact and paretic sides, with a frequency of 100 Hz, pulse width of 200 microseconds, and a biphasic symmetric pulse for 30 minutes. The current intensity was adjusted to a level that induced visible muscle contractions and was set to twice the sensory threshold. Self-adhesive electrodes, measuring 5x5 cm, were placed on the extensor surface of the forearm, 5 cm distal to the olecranon, parallel to the long axis of the muscle. Electrical stimulation was applied using the Cefar Rehab X2 device (DJO France SAS).
Study: NCT06771869

Intervention type: DIAGNOSTIC_TEST
Intervention: Sodium balance
Description: cumulative sodium balance and cumulative fluid balance will be estimated in the first three days after admission
Study: NCT04750200

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embolization of the Middle Meningeal Artery
Description: EMMA is performed inside of the blood vessels where tiny catheters are used to deliver polymer embolic agents to block small blood vessels supplying the brain coverings. A particulate polymer embolic agent (also called polyvinyl acrylate, PVA) or a liquid embolic agents (polymers of ethynyl vinyl alcohol, EVOH) can be used.
Study: NCT06252285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVt Vaccine
Description: Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Suspension of virus in a nasal spray-Route of administration:Intranasal
Study: NCT06276374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patients who are scheduled to undergo carotid artery stenting
Description: * Arm A : Single antiplatelet therapy (SAPT) with aspirin or clopidogrel~  - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)~* Arm B : Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients who are scheduled to undergo carotid artery stenting
Description: * Arm A : Single antiplatelet therapy (SAPT) with aspirin or clopidogrel~  - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.)→ Randomization → 11 months of single antiplatelet therapy (100mg aspirin q.d. or 75mg clopidogrel q.d.)~* Arm B : Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel - 1 month of dual antiplatelet therapy(100mg aspirin q.d. and 75mg clopidogrel q.d.) → Randomization → 11 months of dual antiplatelet therapy (100mg aspirin q.d. and 75mg clopidogrel q.d.)
Study: NCT06491368

Intervention type: PROCEDURE
Intervention: Cesarean Delivery
Description: A Pfannenstiel abdominal incision is made. The skin and rectus sheath are transversely opened using sharp dissection, and the rectus sheath is separated from the underlying rectus abdominis muscles. The peritoneum is then longitudinally opened using sharp dissection. A transverse incision is made in the lower segment of the uterus, which is subsequently closed with two layers of continuous sutures. Both peritoneal layers are closed with continuous sutures. The fascia is closed using either continuous or interrupted sutures. Finally, the skin is closed with either interrupted sutures or a continuous intracutaneous suture.

Intervention type: PROCEDURE
Intervention: Cesarean Delivery
Description: A Pfannenstiel abdominal incision is made. The skin and rectus sheath are transversely opened using sharp dissection, and the rectus sheath is separated from the underlying rectus abdominis muscles. The peritoneum is then longitudinally opened using sharp dissection. A transverse incision is made in the lower segment of the uterus, which is subsequently closed with two layers of continuous sutures. Both peritoneal layers are closed with continuous sutures. The fascia is closed using either continuous or interrupted sutures. Finally, the skin is closed with either interrupted sutures or a continuous intracutaneous suture.

Intervention type: PROCEDURE
Intervention: Cesarean Delivery
Description: A Pfannenstiel abdominal incision is made. The skin and rectus sheath are transversely opened using sharp dissection, and the rectus sheath is separated from the underlying rectus abdominis muscles. The peritoneum is then longitudinally opened using sharp dissection. A transverse incision is made in the lower segment of the uterus, which is subsequently closed with two layers of continuous sutures. Both peritoneal layers are closed with continuous sutures. The fascia is closed using either continuous or interrupted sutures. Finally, the skin is closed with either interrupted sutures or a continuous intracutaneous suture.
Study: NCT06082804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APN and medical management
Description: Patients are followed by the advanced practice nurse and the hematologist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Description: Patients are followed by the hematologist only (standard of care).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Description: EORTC-QLQ-C30 questionnaire

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life assessment
Description: EORTC-QLQ-C30 questionnaire

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment compliance assessment
Description: GIRERD questionnaire

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment compliance assessment
Description: GIRERD questionnaire
Study: NCT04828954

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization for 2-weeks postoperative
Description: Non-removable thumb spica plaster postoperative splint immobilization worn for 2 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization for 6-weeks postoperative
Description: Non-removable postoperative thumb spica splint immobilization worn for 2 weeks (+/- 3 days), to be transitioned to thumb spica cast for an additional 4 weeks (Total of 6 weeks immobilization)
Study: NCT04682691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin (400mg)
Description: oral Erythromycin (400mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide (10mg)
Description: oral metoclopramide (10mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: naturally flavored water
Description: naturally flavored water
Study: NCT06305676

Intervention type: DIAGNOSTIC_TEST
Intervention: combined HPV 16 DNA and host gene methylation oral biomarker panel
Description: DNA Methylation Profiling

Intervention type: DIAGNOSTIC_TEST
Intervention: combined HPV 16 DNA and host gene methylation oral biomarker panel
Description: DNA Methylation Profiling
Study: NCT06543355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Battlefield Acupuncture + National Acupuncture Detoxification Association protocol
Description: The delivery of modified BFA + NADA will be administered in a setting designed to ensure that patients are comfortable, with their backs well-supported. With regards to needling technique, participants' ears will be cleaned, and sterile acupuncture needles will be placed on the BFA or NADA points, using proper technique. Auricular acupuncture needles are thin, between 0.12 - 0.18mm, and are less than 1 inch long. The needles will remain in the ear until the session is complete. On the alternative ear, seeds are another modality of auricular acupuncture treatment that will be used. Seeds are comprised of small circular balls comprised of a natural plant, no more than 1.5 mm diameter size. The seeds are attached to a small piece of adhesive tape and are placed on one's ear. The seeds remain on the ear and the given point can be massaged and stimulated as indicated.
Study: NCT05120557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound liver assessment
Description: The intervention consists in an ultrasound exam performed with the ultrasound medical device subject of the research.
Study: NCT05414734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HHT120
Description: Capsule, oral administration
Study: NCT05806138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat
Description: A starting dose of vericiguat 2.5 mg will be administered in-clinic at the Day 1 visit. Titration visits will occur on Days 14 and 28, with dose escalation to 5 mg and 10 mg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical therapy
Description: All subjects will be followed by a cardiologist throughout the study period and will receive optimal medical therapy for cardiomyopathy/heart failure following the ACCF/AHA and ESC Guidelines for the Management of Heart Failure recommendations, applied individually at the discretion of the treating investigator and in line with individual tolerability. This includes medications such as ßblockers, angiotensin converting enzyme inhibitors(ACEI), angiotensin receptor/neprilysin inhibitor (ARNI), angiotensin receptor blockers (ARB), and mineralocorticoid antagonists
Study: NCT05292651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: percutaneous coronary intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: percutaneous coronary intervention
Study: NCT05414734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HHT120
Description: Capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HHT120
Description: Capsule, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HHT120
Description: Capsule, oral administration
Study: NCT06062446

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Lumbar Puncture
Description: The Investigator will perform the modified LP procedure using the 22 Gg needles Quincke spinal needle (namely, without reinsertion of stylet into the spinal needle after cerebrospinal fluid (CSF) collection before spinal needle removal).
Study: NCT04813718

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omni-Biotic Pro Vi 5
Description: Pre- and probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06250140

Intervention type: DEVICE
Intervention: Tie up device
Description: The recurrence rate of internal hemorrhoids in different treatment methods

Intervention type: DEVICE
Intervention: Tie up device
Description: The recurrence rate of internal hemorrhoids in different treatment methods

Intervention type: DEVICE
Intervention: Tie up device
Description: The recurrence rate of internal hemorrhoids in different treatment methods
Study: NCT05414734

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, oral administration
Study: NCT05254743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Administered orally.
Study: NCT05131607

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine MRI
Description: After completion of the standard prone MRI sequences the patient will be positioned supine, coils will be placed and baseline images will be obtained. Then a second dose of contrast equal to the first dose will be given, and additional images will be obtained
Study: NCT05402826

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral zinc + vitamin E
Description: In the zinc + vitamin E supplementation group, patients will receive a cumulative dose of 120 mg of oral zinc supplementation plus a cumulative dose of 1200 IU of oral vitamin E before surgery. After surgery, from the second day to the end of the hospital stay, patients receive 30 mg of zinc supplement plus 200 units of vitamin E per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive placebo pills before and after surgery.
Study: NCT04949932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed powder of Lens culinaris, Curcuma longa, Mentha arvensis, Azadirachta indica, and Trigonella foenumgraecum.
Description: Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cicer arietinum powder
Description: Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.